The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Diabetes Drug Delivery Devices Market, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    August 2020

  • Pages
    243

  • View Count
    708

Example Insights

Diabetes-Drug-Delivery-Devices-Market-Context Diabetes-Drug-Delivery-Devices-Market-List-of-devices Diabetes-Drug-Delivery-Devices-Market-Landscape
Diabetes-Drug-Delivery-Devices-Market-Distribution-by-Type-of-Device Diabetes-Drug-Delivery-Devices-Market-Product-Competitiveness-Analysis Diabetes-Drug-Delivery-Devices-Market-Partnerships-and-Collaborations
Diabetes-Drug-Delivery-Devices-Market-Big-Pharma-Initiatives Diabetes-Drug-Delivery-Devices-Market-Forecasted-Opportunity Diabetes-Drug-Delivery-Devices-Market-key-geographical-regions

 

Overview

Diabetes is considered to be among the seventh leading causes of mortality worldwide. The chronic and debilitating nature of the condition has a severe impact on the quality of life of patients. According to the World Health Organization (WHO), more than 400 million individuals across the world are currently suffering from diabetes; this number is estimated to reach over 570 million by 2030. Insulin injection and non-insulin therapies are considered to be the primary treatment options for diabetes management. In addition, a number of innovative drugs / therapies for the treatment and management of diabetes have been developed; these are gradually being introduced into the market. It is worth mentioning that insulin, one of primary therapeutic solutions prescribed for treating diabetes, and a few other medications, require parenteral administration. Moreover, since glycemic control is required multiple times in a day, the frequency of administration of such drugs is high (3-4 times a day). There are multiple concerns surrounding parenteral drug delivery, such as chances of dosing-related errors, risk of microbial contamination and needlestick injuries. Since insulin and other such diabetes medications are usually self-administered, the aforementioned concerns are compounded, given that most patients lack the required medical training and / or are not cautious while self-medicating. As a result, there is a stigma associated with the risks of self-medication, which, in turn, has an impact on the patients’ drug adherence to prescribed regimens. Overall, the therapeutic efficacy is compromised, and patients fail to benefit from the recommended intervention. 

Over the past few years, a number of companies have developed advanced drug delivery solutions, such as insulin pumps, pen injectors / autoinjectors, jet injectors, intranasal drug delivery solutions and microneedle-based patches, in order to address the aforementioned challenges. In addition, the stakeholders are actively focusing on introducing innovative features, such as the development of integrated continuous glucose monitoring (CGM) system (also known as artificial pancreas) with insulin pumps, artificial intelligence algorithms, visual / audible drug delivery confirmation notifications, automatic drug reconstitution, and error alerts. We believe that such efforts are likely to drive growth in this market over the coming years.

Scope of the Report

The “Diabetes Drug Delivery Devices Market, 2020-2030” report features an extensive study of the current market landscape and the likely adoption of diabetes drug delivery devices, over the next decade. The study features a detailed analysis of the key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

  • An overview of the current market landscape of diabetes drug delivery devices available for delivery of insulin and non-insulin drugs, including information on device specifications, such as type of device (insulin pump, pen-injector / autoinjector, jet injector, microneedle patch, nasal delivery system, insulin port, oral delivery system and inhalation device), stage of development (marketed, clinical and preclinical), route of administration (subcutaneous, intramuscular, transdermal, oral, intranasal and others), mode of drug delivery (invasive, minimally invasive and non-invasive), needle attributes (needleless, detachable needle, cannula, hidden needle and fixed needle), type of drug delivery system (mechanical method and electrical method), drug administration speed (fast and slow), device usability (disposable, reusable and reusable (disposable components)), diabetes type (type I diabetes, type II diabetes and diabetes type (unspecified)) and type of drug (insulin and non-insulin). In addition, the report present the details of the companies developing these devices, including information on type of developer (industry and non-industry), year of establishment, company size and location of headquarters.  
  • A detailed competitiveness analysis of diabetes drug delivery devices based on various relevant parameters, such as supplier power (based on the experience / expertise of the developer) and product specifications (type of device, route of administration, diabetes type, needle attributes, availability of needle safety system, self-administration potential, mode of drug delivery, device usability, drug administration speed and development stage). 
  • An analysis of the partnerships that have been inked by the stakeholders in this domain, during the period between 2015 and 2020, covering technology integration agreements, product development agreements, distribution agreements, acquisitions, product commercialization agreements, supply agreements, licensing agreements, product development and commercialization agreements and other relevant types of deals.
  • Elaborate profiles of the prominent players developing diabetes drug delivery devices. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook. 
  • A review of recent initiatives undertaken by big pharma players engaged in this domain. It also features a benchmark analysis of top 10 big pharma players (in terms of annual revenues of 2019), based on their initiatives related to diabetes drug delivery devices.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for diabetes drug delivery devices. Based on multiple parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. The report also features sales forecasts for the overall diabetes drug delivery devices market with a detailed market segmentation on the [A] type of device (pen-injectors, insulin pumps, conventional syringes and others), [B] route of administration (subcutaneous, intravenous and others), [C] diabetes type (type 1 diabetes and type 2 diabetes), [D] device usability (disposable and reusable) and [E] key geographies (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

Key Questions Answered

  • Who are the leading diabetes drug delivery device developers?
  • What are the popular delivery devices currently being marketed / developed in this domain?
  • What novel / advanced features device developers are focusing on to maintain a competitive edge in the market?
  • What kind of partnership models are commonly being adopted by stakeholders in this industry? 
  • What initiatives big pharma companies have taken to expand their existing capabilities and comply with industry benchmarks?
  • What are the factors that are likely to influence the evolution of this market?         
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the diabetes drug delivery devices market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to diabetes and different routes of administration of diabetes drugs. In addition, it provides information on types of devices used for delivery of diabetes drugs. It also features a discussion on the existing challenges and future trends that are likely to impact this emerging market segment. 

Chapter 4 includes an assessment of current market landscape of the devices available for delivery of insulin and non-insulin drugs, based on parameters, such as type of device (insulin pump, pen-injector / autoinjector, jet injector, microneedle patch, nasal delivery system, insulin port, oral delivery system and inhalation device), stage of development (marketed, clinical and preclinical), route of administration (subcutaneous, intramuscular, transdermal, oral, intranasal and others), mode of drug delivery (invasive, minimally invasive and non-invasive), needle attributes (needleless, detachable needle, cannula, hidden needle and fixed needle), type of drug delivery system (mechanical method and electrical method), drug administration speed (fast and slow), device usability (disposable, reusable and reusable (disposable components)), diabetes type (type I diabetes, type II diabetes and diabetes type (unspecified)) and type of drug (insulin and non-insulin). The report also features an analysis of the device developers, based on type of developer (industry and non-industry), year of establishment, company size and location of headquarters, highlighting the leading manufacturers.  

Chapter 5 presents a detailed competitiveness analysis of diabetes drug delivery devices based on various relevant parameters, such as supplier power (based on the experience / expertise of the developer) and product specifications (type of device, route of administration, diabetes type, needle attributes, availability of needle safety system, self-administration potential, mode of drug delivery, device usability, drug administration speed and development stage). 

Chapter 6 features an analysis of the various partnerships and collaborations that have been inked between the players in this market, in the time period 2015-2020 (till July). It provides a brief description on the various types of partnership models (technology integration agreements, product development agreements, distribution agreements, acquisitions, product commercialization agreements, supply agreements, licensing agreements, product development and commercialization agreements and other relevant types of deals) that have been adopted by stakeholders in this domain. Further, it includes analyses based on year of partnership, type of partnership, type of device mentioned in the agreement and most active players. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 7 provides detailed profiles of the prominent companies that develop diabetes drug delivery devices. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook. 

Chapter 8 provides a review of recent initiatives undertaken by big pharma players in this domain. It also features a benchmark analysis of top 10 big pharma players (in terms of annual revenues of 2019), comparing them across various relevant parameters, such as number of marketed diabetes drugs, clinical pipeline, diversity of device portfolio, type of diabetes drug evaluated, type of diabetes evaluated and partnerships.

Chapter 9 presents an insightful market forecast analysis, highlighting the future potential of diabetes drug delivery devices till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of device (pen-injectors, insulin pumps, conventional syringes and others), [B] route of administration (subcutaneous, intravenous and others), [C] diabetes type (type 1 diabetes and type 2 diabetes), [D] device usability (disposable and reusable) and [E] key geographies (North America, Europe, Asia Pacific and rest of the world).

Chapter 10 is a summary of the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the diabetes drug delivery devices market.

Chapter 11 is a collection of interview transcripts of the discussions held with key stakeholders in this market. 

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 13 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. An Overview of Diabetes
3.2.1. Classification of Diabetes
3.2.1.1. Type 1 Diabetes
3.2.1.2. Type 2 Diabetes

3.3. Route of Administration for Diabetes Drugs
3.3.1. Buccal Route
3.3.2. Inhalation Route
3.3.3. Intradermal Route
3.3.4. Intramuscular Route
3.3.5. Intranasal Route
3.3.6. Oral Route
3.3.7. Subcutaneous Route

3.4. Key Challenges Associated with Delivery of Diabetes Drugs
3.5. Diabetes Drug Delivery Devices
3.5.1. Implants
3.5.2. Inhalation Devices
3.5.3. Insulin Ports
3.5.4. Insulin Pumps
3.5.5. Jet Injectors
3.5.6. Microneedle Patches
3.5.7. Nasal Delivery Devices
3.5.8. Pen-Injectors / Autoinjectors

3.6. Concluding Remarks

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Diabetes Drug Delivery Devices: Overall Market Landscape
4.2.1. Analysis by Type of Device
4.2.2. Analysis by Stage of Development
4.2.3. Analysis by Route of Administration
4.2.4. Analysis by Mode of Drug Delivery
4.2.5. Analysis by Needle Attributes
4.2.6. Analysis by Type of Drug Delivery System
4.2.7. Analysis by Drug Administration Speed
4.2.8. Analysis by Device Usability
4.2.9. Analysis by Diabetes Type
4.2.10. Analysis by Type of Drug

4.3. Diabetes Drug Delivery Devices: List of Developers
4.3.1. Analysis by Type of Developer
4.3.2. Analysis by Year of Establishment
4.3.3. Analysis by Company Size
4.3.4. Analysis by Location of Headquarters
4.3.5. Leading Manufacturers: Analysis by Number of Products

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Methodology
5.2.1. Product Competitive Analysis: Diabetes Drug Delivery Devices

6. PARTNERSHIPS AND COLLABORATIONS
6.1. Chapter Overview
6.2. Partnership Models
6.3. Diabetes Drug Delivery Devices: List of Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.3. Analysis by Year and Type of Partnership
6.3.4. Analysis by Type of Device
6.3.5. Most Active Players: Analysis by Number of Partnerships
6.3.6. Geographical Analysis
6.3.6.1. Region-wise Distribution
6.3.6.2. Country-wise Distribution

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Bigfoot Biomedical
7.2.1. Company Overview
7.2.2. Diabetes Drug Delivery Device Portfolio
7.2.3. Recent Developments and Future Outlook

7.3. Debiotech
7.3.1. Company Overview
7.3.2. Diabetes Drug Delivery Device Portfolio
7.3.3. Recent Developments and Future Outlook

7.4. Haselmeier
7.4.1. Company Overview
7.4.2. Diabetes Drug Delivery Device Portfolio
7.4.3. Recent Developments and Future Outlook

7.5. Medtronic
7.5.1. Company Overview
7.5.2. Diabetes Drug Delivery Device Portfolio
7.5.3. Recent Developments and Future Outlook

7.6. Novo Nordisk
7.6.1. Company Overview
7.6.2. Diabetes Drug Delivery Device Portfolio
7.6.3. Recent Developments and Future Outlook
7.7. Roche
7.7.1. Company Overview
7.7.2. Diabetes Drug Delivery Device Portfolio
7.7.3. Recent Developments and Future Outlook

7.8. SOOIL
7.8.1. Company Overview
7.8.2. Diabetes Drug Delivery Device Portfolio
7.8.3. Recent Developments and Future Outlook

7.9. Ypsomed
7.9.1. Company Overview
7.9.2. Diabetes Drug Delivery Device Portfolio
7.9.3. Recent Developments and Future Outlook

8. DIABETES DRUG DELIVERY DEVICES RELATED INITIATIVES OF BIG PHARMA PLAYERS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Initiatives of Big Pharma Players
8.3.1. Analysis by Diversity in Device Portfolio
8.3.2. Analysis by Phase of Development
8.3.3. Analysis by Diabetes Type
8.3.4. Analysis by Type of Drug
8.3.5. Analysis by Number of Partnerships

8.4. Benchmark Analysis of Big Pharma Players
8.4.1. Spider Web Analysis: Company A
8.4.2. Spider Web Analysis: Company B
8.4.3. Spider Web Analysis: Company C
8.4.4. Spider Web Analysis: Company D
8.4.5. Spider Web Analysis: Company E
8.4.6. Spider Web Analysis: Company F

9. MARKET SIZING AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Assumptions
9.3. Overall Diabetes Drug Delivery Devices Market, 2020-2030
9.3.1. Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Type of Device
9.3.2. Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Route of Administration
9.3.3. Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Diabetes Type
9.3.4. Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Device Usability
9.3.5. Diabetes Drug Delivery Devices Market, 2020-2030: Geographical Distribution
9.3.5.1. Diabetes Drug Delivery Devices Market in North America, 2020-2030
9.3.5.2. Diabetes Drug Delivery Devices Market in Europe, 2020-2030
9.3.5.3. Diabetes Drug Delivery Devices Market in Asia Pacific, 2020-2030
9.3.5.4. Diabetes Drug Delivery Devices Market in Rest of the World, 2020-2030

10. CONCLUDING REMARKS
10.1. Chapter Overview
10.2. Key Takeaways

11. EXECUTIVE INSIGHTS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Routes for Diabetes Drug Administration
Figure 3.2 Types of Diabetes Drug Delivery Devices
Figure 3.3 Historical Evolution of Diabetes Drug Delivery Devices
Figure 4.1 Diabetes Drug Delivery Devices: Distribution by Type of Device
Figure 4.2 Diabetes Drug Delivery Devices: Distribution by Stage of Development
Figure 4.3 Diabetes Drug Delivery Devices: Distribution by Type of Device and Stage of Development
Figure 4.4 Diabetes Drug Delivery Devices: Distribution by Route of Administration
Figure 4.5 Diabetes Drug Delivery Devices: Distribution by Type of Device and Route of Administration
Figure 4.6 Diabetes Drug Delivery Devices: Distribution by Mode of Drug Delivery
Figure 4.7 Diabetes Drug Delivery Devices: Distribution by Type of Device and Mode of Drug Delivery
Figure 4.8 Diabetes Drug Delivery Devices: Distribution by Needle Attributes
Figure 4.9 Diabetes Drug Delivery Devices: Distribution by Type of Device and Needle Attribute
Figure 4.10 Diabetes Drug Delivery Devices: Distribution by Type of Drug Delivery System
Figure 4.11 Diabetes Drug Delivery Devices: Distribution by Type of Device and Type of Drug Delivery System
Figure 4.12 Diabetes Drug Delivery Devices: Distribution by Drug Administration Speed
Figure 4.13 Diabetes Drug Delivery Devices: Distribution by Type of Device and Drug Administration Speed
Figure 4.14 Diabetes Drug Delivery Devices: Distribution by Device Usability
Figure 4.15 Diabetes Drug Delivery Devices: Distribution by Type of Device and Device Usability
Figure 4.16 Diabetes Drug Delivery Devices: Distribution by Diabetes Type
Figure 4.17 Diabetes Drug Delivery Devices: Distribution by Type of Device and Diabetes Type
Figure 4.18 Diabetes Drug Delivery Devices: Distribution by Type of Drug
Figure 4.19 Diabetes Drug Delivery Devices: Distribution by Type of Device and Type of Drug
Figure 4.20 Diabetes Drug Delivery Device Developers: Distribution by Type of Developer
Figure 4.21 Diabetes Drug Delivery Device Developers: Distribution by Year of Establishment
Figure 4.22 Diabetes Drug Delivery Device Developers: Distribution by Company Size
Figure 4.23 Diabetes Drug Delivery Device Developers: Geographical Distribution by Location of Headquarters
Figure 5.1 Diabetes Drug Delivery Devices: Dot Plot Analysis
Figure 5.2 Product Competitiveness Analysis: Diabetes Drug Delivery Devices
Figure 6.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 6.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 6.4 Partnerships and Collaborations: Distribution by Type of Device
Figure 6.5 Most Active Players: Analysis by Number of Partnerships
Figure 6.6 Partnerships and Collaborations: Region-wise Distribution
Figure 6.7 Partnerships and Collaborations: Country-wise Distribution
Figure 8.1 Big Pharma Initiatives: Heat Map Analysis of Top Pharmaceutical Companies
Figure 8.2 Big Pharma Initiatives: Distribution by Diversity in Device Portfolio
Figure 8.3 Big Pharma Initiatives: Distribution by Phase of Development of Diabetes Drugs
Figure 8.4 Big Pharma Initiatives: Distribution by Type of Diabetes
Figure 8.5 Big Pharma Initiatives: Distribution by Type of Drug Evaluated
Figure 8.6 Big Pharma Initiatives: Distribution by Number of Partnerships
Figure 8.7 Spider Web Analysis: Company A
Figure 8.8 Spider Web Analysis: Company B
Figure 8.9 Spider Web Analysis: Company C
Figure 8.10 Spider Web Analysis: Company D
Figure 8.11 Spider Web Analysis: Company E
Figure 8.12 Spider Web Analysis: Company F
Figure 9.1 Overall Diabetes Drug Delivery Devices Market, 2020-2030 (USD Billion)
Figure 9.2 Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Type of Device (USD Billion)
Figure 9.3 Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Route of Administration (USD Billion)
Figure 9.4 Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Diabetes Type (USD Billion)
Figure 9.5 Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Device Usability (USD Billion)
Figure 9.6 Diabetes Drug Delivery Devices Market, 2020-2030: Geographical Distribution (USD Billion)
Figure 9.7 Diabetes Drug Delivery Devices Market in North America, 2020-2030 (USD Billion)
Figure 9.8 Diabetes Drug Delivery Devices Market in Europe, 2020-2030 (USD Billion)
Figure 9.9 Diabetes Drug Delivery Devices Market in Asia Pacific, 2020-2030 (USD Billion)
Figure 9.10 Diabetes Drug Delivery Devices Market in Rest of the World, 2020-2030 (USD Billion)

List Of Tables

Table 3.1 Blood Sugar Levels observed in Diabetic Patients
Table 4.1 List of Diabetes Drug Delivery Devices
Table 4.2 Diabetes Drug Delivery Devices: List of Developers
Table 6.1 Diabetes Drug Delivery Devices: List of Partnerships, 2015-2020 (Till June)
Table 7.1 Leading Diabetes Drug Delivery Device Developers
Table 7.2 Bigfoot Biomedical: Company Overview
Table 7.3 Bigfoot Biomedical: Diabetes Drug Delivery Devices
Table 7.4 Bigfoot Biomedical: Recent Developments and Future Outlook
Table 7.5 Debiotech: Company Overview
Table 7.6 Debiotech: Diabetes Drug Delivery Devices
Table 7.7 Debiotech: Recent Developments and Future Outlook
Table 7.8 Haselmeier: Company Overview
Table 7.9 Haselmeier: Diabetes Drug Delivery Devices
Table 7.10 Haselmeier: Recent Developments and Future Outlook
Table 7.11 Medtronic: Company Overview
Table 7.12 Medtronic: Diabetes Drug Delivery Devices
Table 7.13 Medtronic: Recent Developments and Future Outlook
Table 7.14 Novo Nordisk: Company Overview
Table 7.15 Novo Nordisk: Diabetes Drug Delivery Devices
Table 7.16 Novo Nordisk: Recent Developments and Future Outlook
Table 7.17 Roche: Company Overview
Table 7.18 Roche: Diabetes Drug Delivery Devices
Table 7.19 Roche: Recent Developments and Future Outlook
Table 7.20 SOOIL: Company Overview
Table 7.21 SOOIL: Diabetes Drug Delivery Devices
Table 7.22 SOOIL: Recent Developments and Future Outlook
Table 7.23 Ypsomed: Company Overview
Table 7.24 Ypsomed: Diabetes Drug Delivery Devices
Table 7.25 Ypsomed: Recent Developments and Future Outlook
Table 8.1 Big Pharma Players: Top Big Pharma in Diabetes Domain
Table 8.2 Big Pharma Players: Spider-Web Analysis (Input Data)
Table 10.1 Diabetes Drug Delivery Devices: Summary of the Report
Table 11.1 Cambridge Consultants: Company Snapshot
Table 12.1 Diabetes Drug Delivery Devices: Distribution by Type of Device
Table 12.2 Diabetes Drug Delivery Devices: Distribution by Stage of Development
Table 12.3 Diabetes Drug Delivery Devices: Distribution by Type of Device and Stage of Development
Table 12.4 Diabetes Drug Delivery Devices: Distribution by Route of Administration
Table 12.5 Diabetes Drug Delivery Devices: Distribution by Type of Device and Route of Administration
Table 12.6 Diabetes Drug Delivery Devices: Distribution by Mode of Drug Delivery
Table 12.7 Diabetes Drug Delivery Devices: Distribution by Type of Device and Mode of Drug Delivery
Table 12.8 Diabetes Drug Delivery Devices: Distribution by Needle Attribute
Table 12.9 Diabetes Drug Delivery Devices: Distribution by Type of Device and Needle Attribute
Table 12.10 Diabetes Drug Delivery Devices: Distribution by Type of Drug Delivery System
Table 12.11 Diabetes Drug Delivery Devices: Distribution by Type of Device and Type of Drug Delivery System
Table 12.12 Diabetes Drug Delivery Devices: Distribution by Drug Administration Speed
Table 12.13 Diabetes Drug Delivery Devices: Distribution by Type of Device and Drug Administration Speed
Table 12.14 Diabetes Drug Delivery Devices: Distribution by Device Usability
Table 12.15 Diabetes Drug Delivery Devices: Distribution by Type of Device and Device Usability
Table 12.16 Diabetes Drug Delivery Devices: Distribution by Diabetes Type
Table 12.17 Diabetes Drug Delivery Devices: Distribution by Type of Device and Diabetes Type
Table 12.18 Diabetes Drug Delivery Devices: Distribution by Type of Drug
Table 12.19 Diabetes Drug Delivery Devices: Distribution by Type of Device and Type of Drug
Table 12.20 Diabetes Drug Delivery Device Developers: Distribution by Type of Developer
Table 12.21 Diabetes Drug Delivery Device Developers: Distribution by Year of Establishment
Table 12.22 Diabetes Drug Delivery Device Developers: Distribution by Company Size
Table 12.23 Diabetes Drug Delivery Device Developers: Geographical Distribution by Location of Headquarters
Table 12.24 Partnerships and Collaborations: Distribution by Year of Partnership
Table 12.25 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.26 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 12.27 Partnerships and Collaborations: Distribution by Type of Device
Table 12.28 Most Active Players: Analysis by Number of Partnerships
Table 12.29 Partnerships and Collaborations: Region-wise Distribution
Table 12.30 Partnerships and Collaborations: Country-wise Distribution
Table 12.31 Overall Diabetes Drug Delivery Devices Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.32 Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Type of Device (USD Billion)
Table 12.33 Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Route of Administration (USD Billion)
Table 12.34 Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Diabetes Type (USD Billion)
Table 12.35 Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Device Usability (USD Billion)
Table 12.36 Diabetes Drug Delivery Devices Market, 2020-2030: Geographical Distribution (USD Billion)
Table 12.37 Diabetes Drug Delivery Devices Market in North America, Conservative, Base and Optimistic Scenarios, 2020-2030: (USD Billion)
Table 12.38 Diabetes Drug Delivery Devices Market in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030: (USD Billion)
Table 12.39 Diabetes Drug Delivery Devices Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030: (USD Billion)
Table 12.40 Diabetes Drug Delivery Devices Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030: (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report. 

  1. AstraZeneca 
  2. Abbott 
  3. Activa Brand Products 
  4. Aerami Therapeutics 
  5. Aijex Pharma International 
  6. AMSL Diabetes 
  7. Antares Pharma 
  8. AptarGroup 
  9. Asante Solutions 
  10. Ascensia Diabetes Care 
  11. AstraZeneca 
  12. Australasian Medical & Scientific 
  13. Bayer 
  14. Berlin-Chemie
  15. Beta Bionics 
  16. Bigfoot Biomedical 
  17. Biocon 
  18. Biocorp
  19. Biomm 
  20. Boehringer Ingelheim 
  21. Cambridge Consultants 
  22. Cambridge Design Partnership 
  23. Capital District Physicians’ Health Plan 
  24. Caretek Medical 
  25. CeQur 
  26. Chengdu Municipal Government 
  27. Chinese Academy of Sciences 
  28. Cipla 
  29. Common Sensing 
  30. Companion Medical 
  31. Debiotech 
  32. Dexcom 
  33. Diabeloop 
  34. Eli Lilly 
  35. EOFlow 
  36. European Pharma Group 
  37. Generex Biotechnology 
  38. Glooko 
  39. Haselmeier 
  40. Henry Schein 
  41. Huons 
  42. Injex UK 
  43. Inovio Pharmaceuticals 
  44. Institute for Basic Science 
  45. Insulet 
  46. Insuline Medical 
  47. IntraPump Infusion Systems 
  48. i-SENS 
  49. JDRF 
  50. Johnson & Johnson 
  51. KBIO Health 
  52. Klue 
  53. Lupin 
  54. MannKind 
  55. Medtronic 
  56. Medtrum Technologies 
  57. A.Menarini Diagnostics 
  58. Merck 
  59. MK Medical 
  60. MOVI 
  61. Mystic Pharmaceuticals 
  62. National Institute of Biomedical Imaging and Bioengineering 
  63. Nemaura Pharma 
  64. North Carolina State University 
  65. Novo Nordisk 
  66. Nutrino Health (acquired by Medtronic)
  67. One Drop 
  68. Owen Mumford 
  69. Pacific Diabetes Technologies 
  70. PercuSense
  71. PharmaSens 
  72. Rimidi 
  73. Roche 
  74. Rubin Medical 
  75. Samsung 
  76. Sanofi 
  77. Senseonics 
  78. SFC Fluidics 
  79. SOOIL 
  80. Stevanato Group 
  81. Takeda 
  82. Tandem Diabetes Care 
  83. Tanner Pharma Group 
  84. Theras Group 
  85. Tidepool 
  86. Timesulin 
  87. TypeZero Technologies 
  88. University of California, Santa Barbara 
  89. UCLA Bioengineering 
  90. ViCentra 
  91. Ypsomed 
  92. Zealand Pharma

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com